Browsing by Author Byrne, Michael J.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2008Anemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study GroupCoates, Alan; Aebi, Stefan; Byrne, Michael J.; Cole, Bernard; Colleoni, Marco; Crivellari, Diana; et, al; Gianni, Lorenzo; Holmberg, Stig B.; Panzini, Ilaria; Snyder, Raymond; School of Public Health: Public HealthAnemia during adjuvant non-taxane chemotherapy for early breast cancer: Incidence and risk factors from two trials of the International Breast Cancer Study Group, Supportive Care in Cancer, vol.16,(1),2008,pp 67-74
2004Assessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module.Nowak, Anna; Stockler, Martin; Byrne, Michael J.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAssessing Quality Of Life During Chemotherapy For Pleural Mesothelioma: Feasibility, Validity, And Results Of Using The European Organization For Research And Treatment Of Cancer Core Quality Of Life Questionnaire And Lung Cancer Module., Journal of Clinical Oncology, vol.22,(15),2004,pp 3172-3180
2011Capecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast CancerCoates, Alan; Gebski, Val; Grimison, Peter; Stockler, Martin; Wilcken, Nicholas; Zannino, Diana; Ackland, Stephen; Byrne, Michael J.; Fitzharris, B; Fong, A.; Forbes, John; Francis, Prudence; Gainford, Corona; Harvey, V; Nowak, Anna; Paksec, Lisa; Simes, John; Sourjina, Tatiana; Van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Western Clinical School: Medicine (Westmead); School of Public Health: NH&MRC Clinical Trials CentreCapecitabine Versus Classical Cyclophosphamide, Methotrexate, and Fluorouracil As First-Line Chemotherapy for Advanced Breast Cancer, Journal of Clinical Oncology, vol.29, 34, 2011,pp 4498-4504
2003Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node statusCoates, Alan; Byrne, Michael J.; Castiglione-Gertsch, Monica; Collins, John; Cortes-Funes, Hernan; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Golouh, Rastko; Grigolato, Piergioranni; Lindtner, Jurii; Litman, H; Maffini, Fausto; Martinez-Tello, Francisco J.; Masullo, Michele; Price, Karen; Simoncini, Edda; Spataro, Vito J.; Viale, Giuseppe; School of Public Health: Public HealthDecreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status, Cancer, vol.97,(7),2003,pp 1591-1600
2013A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural MesotheliomaBrown, Christopher; Pavlakis, Nick; Stockler, Martin; Bibby, David C; Boyer, Michael; Byrne, Michael J.; Creaney, Jenette; Hughes, Brett; Kremmidiotis, Gabriel; Leske, Annabell; Millward, Michael; Mitchell, Paul L.; Nowak, Anna; School of Public Health: NH&MRC Clinical Trials Centre; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreA phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma, Lung Cancer, vol.81, 3, 2013,pp 422-427
2006A randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatmentCoates, Alan; Gebski, Val; Simes, Robert John; Sourjina, Tatiana; Stockler, Martin; Ackland, Stephen P.; Byrne, Michael J.; Finch, K; Fitzharris, B; Forbes, John F.; Frances, P; Harvey, V; Kato-Fong, A; Lindsay, Dianne; Paksec, Lisa; van Hazel, Guy; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA randomized trial of capecitabine given intermittently versus continuously versus classical CMF as first line chemotherapy for women with advanced breast cancer unsuited to more intensive treatment, Breast Cancer Research and Treatment, vol.100, Supplement 1,pp S278-S278
2013Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneCoates, Alan; Gebski, Val; Lee, Chee Khoon; Simes, Robert John; Tattersall, Martin; Veillard, Anne-Sophie; Brigham, Brian; Byrne, Michael J.; Forbes, John; Harvey, V; School of Public Health: Public Health; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; Central Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials CentreTrade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisone, SpringerPlus, vol.2, 391, 2013,pp 1-10